We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | NYSE:TEVA | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.465 | 2.91% | 16.465 | 16.57 | 16.07 | 16.07 | 5,089,633 | 16:14:58 |
From May 2023 to May 2024
By Dean Seal
New York's attorney general said Friday that final approval has been granted for $17.3 billion in settlements with drug makers and pharmacies over the opioid crisis.
The approvals resolve cases from multiple states accusing Teva Pharmaceuticals and Allergan as well as CVS and Walgreens of downplaying the risk of painkillers and perpetuating the deadly opioid epidemic.
The settlement deals will become effective in the coming weeks and the settlement funds will start becoming available to state and local governments by the end of the year.
New York is set to receive more than $1 billion and has already started receiving payments from Teva for the trial premium as part of the state's previous landmark liability verdict against the company, the New York AG's office said.
"These funds will help with opioid abatement, education, and treatment efforts in our communities," Attorney General Letitia James said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 09, 2023 10:24 ET (14:24 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Teva Pharmaceutical Indu... Chart |
1 Month Teva Pharmaceutical Indu... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
